

Kevin D Burns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3105230/publications.pdf>

Version: 2024-02-01

66
papers

2,752
citations

394390

19
h-index

182417

51
g-index

67
all docs

67
docs citations

67
times ranked

4888
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	1.7	431
2	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	1.7	400
3	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	1.7	269
4	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	1.7	221
5	Human Endothelial Colony-Forming Cells Protect against Acute Kidney Injury. American Journal of Pathology, 2015, 185, 2309-2323.	3.8	186
6	Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury. Kidney International, 2016, 90, 1238-1250.	5.2	177
7	Urinary Podocyte Microparticles Identify Prealbuminuric Diabetic Glomerular Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 1401-1407.	6.1	117
8	Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney International, 2014, 86, 1057-1058.	5.2	93
9	High glucose increases the formation and pro-oxidative activity of endothelial microparticles. Diabetologia, 2017, 60, 1791-1800.	6.3	79
10	Receptor-Ligand Interaction Mediates Targeting of Endothelial Colony Forming Cell-derived Exosomes to the Kidney after Ischemic Injury. Scientific Reports, 2018, 8, 16320.	3.3	65
11	Characterization of Angiotensin-Converting Enzyme 2 Ectodomain Shedding from Mouse Proximal Tubular Cells. PLoS ONE, 2014, 9, e85958.	2.5	51
12	The emerging role of angiotensin-converting enzyme-2 in the kidney. Current Opinion in Nephrology and Hypertension, 2007, 16, 116-121.	2.0	33
13	The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 312, F335-F342.	2.7	33
14	Differential renal effects of candesartan at high and ultra-high doses in diabetic mice—potential role of the ACE2/AT2R/Mas axis. Bioscience Reports, 2016, 36, .	2.4	32
15	Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2). Methods in Molecular Biology, 2017, 1527, 101-115.	0.9	32
16	The role of angiotensin II-stimulated renal tubular transport in hypertension. Current Hypertension Reports, 2003, 5, 165-171.	3.5	28
17	PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes. Diabetologia, 2016, 59, 1318-1328.	6.3	28
18	Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney International Reports, 2021, 6, 2095-2104.	0.8	23

#	ARTICLE	IF	CITATIONS
19	PGE2 EP1 receptor inhibits vasopressin-dependent water reabsorption and sodium transport in mouse collecting duct. <i>Laboratory Investigation</i> , 2018, 98, 360-370.	3.7	22
20	Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, e45-e47.	8.6	22
21	Kidney, Cardiac, and Safety Outcomes Associated With β -Blockers in Patients With CKD: A Population-Based Cohort Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 178-189.e1.	1.9	21
22	Sex diversity in proximal tubule and endothelial gene expression in mice with ischemic acute kidney injury. <i>Clinical Science</i> , 2020, 134, 1887-1909.	4.3	21
23	C-peptide as a Therapy for Kidney Disease: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0127439.	2.5	19
24	Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. <i>Canadian Journal of Diabetes</i> , 2021, 45, 162-166.e1.	0.8	19
25	The Effect of Angiotensin-(1-7) in Mouse Unilateral Ureteral Obstruction. <i>American Journal of Pathology</i> , 2015, 185, 729-740.	3.8	18
26	Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events in Women of Advanced Age. <i>Hypertension</i> , 2019, 74, 645-651.	2.7	18
27	Short Daily versus Conventional Hemodialysis for Hypertensive Patients: A Randomized Cross-Over Study. <i>PLoS ONE</i> , 2014, 9, e97135.	2.5	16
28	Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors. <i>Laboratory Investigation</i> , 2015, 95, 1044-1055.	3.7	15
29	Protein Kinase C- δ Mediates Shedding of Angiotensin-Converting Enzyme 2 from Proximal Tubular Cells. <i>Frontiers in Pharmacology</i> , 2016, 7, 146.	3.5	14
30	micro-RNA-486-5p protects against kidney ischemic injury and modifies the apoptotic transcriptome in proximal tubules. <i>Kidney International</i> , 2021, 100, 597-612.	5.2	14
31	Urinary angiotensinogen as a biomarker of chronic kidney disease: ready for prime time?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3010-3013.	0.7	13
32	Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease. <i>American Journal of Nephrology</i> , 2019, 49, 328-330.	3.1	13
33	Performance of the 2021 Race-Free CKD-EPI Creatinine- and Cystatin C-Based Estimated GFR Equations Among Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2022, 80, 462-472.e1.	1.9	13
34	Association Between Newborn Metabolic Profiles and Pediatric Kidney Disease. <i>Kidney International Reports</i> , 2018, 3, 691-700.	0.8	12
35	The association of urinary sodium excretion and the need for renal replacement therapy in advanced chronic kidney disease: a cohort study. <i>BMC Nephrology</i> , 2016, 17, 123.	1.8	11
36	Changes in Body Weight Before and After Kidney Donation. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811984720.	1.1	11

#	ARTICLE	IF	CITATIONS
37	Prostaglandin E2 receptor EP1 (PGE2/EP1) deletion promotes glomerular podocyte and endothelial cell injury in hypertensive TTRhRen mice. <i>Laboratory Investigation</i> , 2020, 100, 414-425.	3.7	11
38	miRNA-486-5p: signaling targets and role in non-malignant disease. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	11
39	Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. <i>JAMA Network Open</i> , 2021, 4, e2123365.	5.9	10
40	Circulating Angiogenic Factors in a Pregnant Woman on Intensive Hemodialysis: A Case Report. <i>Canadian Journal of Kidney Health and Disease</i> , 2016, 3, 96.	1.1	9
41	Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging. <i>PLoS ONE</i> , 2017, 12, e0177451.	2.5	8
42	The KRESCENT Program: An initiative to match supply and demand for kidney research in Canada. <i>Clinical and Investigative Medicine</i> , 2010, 33, 356.	0.6	8
43	Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease. <i>Canadian Journal of Cardiology</i> , 2017, 33, 611-618.	1.7	7
44	An evaluation of renin-angiotensin system markers in youth with type 2 diabetes and associations with renal outcomes. <i>Pediatric Diabetes</i> , 2020, 21, 1102-1109.	2.9	7
45	Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. <i>BMJ Open</i> , 2020, 10, e040768.	1.9	7
46	Comparative analysis of hypertensive nephrosclerosis in animal models of hypertension and its relevance to human pathology. <i>Glomerulopathy. PLoS ONE</i> , 2022, 17, e0264136.	2.5	7
47	The impact of intervention strategies that target arterial stiffness in end-stage renal disease: a systematic review protocol. <i>Systematic Reviews</i> , 2016, 5, 118.	5.3	6
48	The therapeutic effects of microRNAs in preclinical studies of acute kidney injury: a systematic review protocol. <i>Systematic Reviews</i> , 2019, 8, 235.	5.3	6
49	A Systematic Review and Meta-analysis of Nonpharmacologic-based Interventions for Aortic Stiffness in End-Stage Renal Disease. <i>Kidney International Reports</i> , 2019, 4, 1109-1121.	0.8	6
50	A novel method for comparison of arterial remodeling in hypertension: Quantification of arterial trees and recognition of remodeling patterns on histological sections. <i>PLoS ONE</i> , 2019, 14, e0216734.	2.5	6
51	Pharmacologic Therapies for Aortic Stiffness in End-Stage Renal Disease: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812090697.	1.1	6
52	Therapeutic effects of micro-RNAs in preclinical studies of acute kidney injury: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021, 11, 9100.	3.3	6
53	Reproducibility of Carotid-Femoral Pulse Wave Velocity in End-Stage Renal Disease Patients: Methodological Considerations. <i>Canadian Journal of Kidney Health and Disease</i> , 2016, 3, 109.	1.1	5
54	Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib. <i>Journal of Clinical Hypertension</i> , 2020, 22, 678-682.	2.0	5

#	ARTICLE	IF	CITATIONS
55	Pincer nails following arteriovenous fistula creation. <i>Kidney International</i> , 2015, 88, 918.	5.2	4
56	The KRESCENT Program (2005-2015). <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811769335.	1.1	4
57	Isolated Penile Calciphylaxis Diagnosed by Ultrasound Imaging in a New Dialysis Patient: A Case Report. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110258.	1.1	3
58	The impact of measuring split kidney function on post-donation kidney function: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0253609.	2.5	3
59	Renal Hemodynamics and Renin-Angiotensin-Aldosterone System Profiles in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, , .	1.7	3
60	A Unique Case of Metformin-Associated Lactic Acidosis. <i>Case Reports in Nephrology</i> , 2018, 2018, 1-5.	0.4	2
61	Effects of living kidney donation on arterial stiffness: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e045518.	1.9	2
62	Cannabis and Cigarette Use Before and After Living Kidney Donation. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812199724.	1.1	2
63	Re: Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. <i>Kidney International</i> , 2015, 88, 915.	5.2	1
64	MicroRNA in Human Acute Kidney Injury: A Systematic Review Protocol. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110099.	1.1	1
65	Case Report: Segmental Arterial Mediolytic, a Rare Cause of Hypertension. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812095088.	1.1	0
66	Brief ACE Inhibition Produces Persistent Changes That Protect Heart but Not Kidney From Lâ€NAME Induced Damage. <i>FASEB Journal</i> , 2009, 23, 1017.44.	0.5	0